Sign in

    Christopher James Richardson • Jefferies

    Christopher James Richardson is a Vice President and equity research analyst at Jefferies, specializing in coverage of the energy sector with a particular focus on upstream oil and gas companies. He provides research and investment recommendations on firms such as BP, Chevron, and Shell, delivering actionable insights for institutional investors. Richardson began his career in finance after completing his master's degree and joined Jefferies in the early 2020s, following prior experience at another leading financial institution. He holds FINRA Series 7 and 63 securities licenses and is recognized for his strong analytical skills and contributions to sector research.

    Christopher James Richardson's questions to SCHOTT Pharma AG & Co KgaA (SHTPY) leadership

    Christopher James Richardson's questions to SCHOTT Pharma AG & Co KgaA (SHTPY) leadership • Q4 2024

    Question

    Christopher James Richardson from Jefferies asked about the level of High-Value Solutions (HVS) vial adoption assumed in the 2025 guidance, given slower industry growth. He also inquired about the relative profitability of HVS vials compared to syringes.

    Answer

    CEO Andreas Reisse explained that HVS vials are still a minor but growing part of the business, with expected growth in ready-to-use vials for applications like ADCs. CFO Dr. Almuth Steinkuhler added that while much of the business is currently sampling, a third large-scale commercial order will contribute to growth. She clarified that at commercial scale, the profitability of ready-to-use vials is approximately at a similar level to that of syringes.

    Ask Fintool Equity Research AI